1. Home
  2. UCAR vs GOVX Comparison

UCAR vs GOVX Comparison

Compare UCAR & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$1.45

Market Cap

9.2M

ML Signal

HOLD

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$0.21

Market Cap

7.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCAR
GOVX
Founded
2013
2001
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
7.8M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
UCAR
GOVX
Price
$1.45
$0.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$5.00
$7.00
AVG Volume (30 Days)
14.4K
3.7M
Earning Date
10-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,816,075.00
$3,353,560.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
57.22
8.52
52 Week Low
$1.43
$0.12
52 Week High
$9.43
$2.75

Technical Indicators

Market Signals
Indicator
UCAR
GOVX
Relative Strength Index (RSI) 24.03 35.02
Support Level $1.57 $0.16
Resistance Level $1.80 $0.22
Average True Range (ATR) 0.16 0.04
MACD -0.01 -0.00
Stochastic Oscillator 8.51 34.27

Price Performance

Historical Comparison
UCAR
GOVX

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: